Ceruletide, an analog of cholecystokinin octapeptide: New perspectives on its efficacy

CNS Drug Reviews

Volumn 5, Issue 2, 1999, Pages 145-164

  Kuroki, Toshihide ^a   Etou, Kazuko ^b   Uchimura, Hideyuki ^c  

^a SAGA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c Hizen National Mental Hospital   (Japan)

Author keywords

Ceruletide; Cholecystokinin receptor; Dopamine; Memory and cognitive functions; Schizophrenia; Tardive dyskinesia

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; CERULETIDE; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CHOLECYSTOKININ OCTAPEPTIDE DERIVATIVE; DOPAMINE; PLACEBO; TETRAGASTRIN;

ABDOMINAL DISCOMFORT; ANXIETY NEUROSIS; CLINICAL TRIAL; COGNITION; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG EFFICACY; HUMAN; INTRACEREBRAL DRUG ADMINISTRATION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MEMORY; NAUSEA; NEUROPHARMACOLOGY; NEUROPSYCHIATRY; NONHUMAN; NUCLEUS ACCUMBENS; PANIC; REVIEW; SCHIZOPHRENIA; SENILE DEMENTIA; SUBCUTANEOUS DRUG ADMINISTRATION; TACHYCARDIA; TARDIVE DYSKINESIA; TRANQUILIZING ACTIVITY; VERTIGO; VOMITING;

EID: 0032843920     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1999.tb00095.x     Document Type: Review

References (105)

1. Akaike A, Tamura Y, Sato Y, et al. Cholecystokinin-induced protection of cultured cortical neurons against glutamate neurotoxicity. Brain Res 1991;557:303-307.
2. Anastasi A, Erspamer V, Endean R. Isolation and structure of caerulein, an active decapeptide from the skin of Hyla caerulea. Experientia 1967;23:699-100.
3. Ashizawa T, Saito T, Takahata N. Effects of ceruletide on perioral movements and the dopamine receptor-adenylate cyclase system in rats chronically treated with fluphenazine. Psychopharmacology 1996;125:185-194.
4. Banks WA, Kastin AJ. Permeability of the blood-brain barrier to neuropeptides: The case for penetration. Psychoneuroendocrinology 1985;10:385-399.
5. Basar-Eroglu C, Basar E, Zetler G. Effects of ceruletide and haloperidol on auditory evoked potentials in the cat brain. Int J Neurosci 1996;85:131-146.
6. Basso N, Materia A, D'Intinosante V, et al. Effect of ceruletide on pituitary-hypothalamic peptides and on emotion in man. Peptides (Suppl 2) 1981;2:71-75.
7. Bernardi L, Bosisio G, de Castiglione R, Goffredo O. Synthesis of caerulein. Experientia 1967:23:700-702.
8. Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder: Clinical and behavioral findings. Arch Gen Psychiatry 1991;48:603-610.
9. Bruno G, Ruggieri S, Chase TN, Bakker K, Tamminga CA. Caerulein treatment of Parkinson's disease. Clin Neuropharmacol 1985;8:266-270.
10. Chieli T, Bertazzoli C, Ferni G, Dell'Oro I, Capella C, Solcia E. Experimental toxicology of caerulein. Toxicol Appl Pharmacol 1972;23:480-491.
11. Crawley JN. Clarification of the behavioral functions of peripheral and central cholecystokinin: Two separate peptide pools. Peptides (Suppl 2) 1985;6:129-136.
12. Crawley JN. Cholecystokinin modulates dopamine-mediated behaviors: Differential actions in medial posterior versus anterior nucleus accumbens. Ann NY Acad Sci 1994;713:138-142.
13. Crawley JN, Corwin RL. Biological actions of cholecystokinin. Peptides 1994;15:731-755.
14. De Witte P, Gewiss M, Roques B, Vanderhaeghen JJ. Neuroleptic-like properties of cholecystokinin analogs: Distinctive mechanisms underlying similar behavioral profiles depending on the route of administration. Peptides 1988;9:739-743.
15. Dodt C, Sarnighausen HE, Pietrowsky R, Fehm HL, Born J. Ceruletide improves event-related potential indicators of cognitive processing in young but not in elderly humans. J Clin Psychopharmacol 1996;16:440-445.
16. Eigyo M, Katsuura G, Shintaku H, et al. Systemic administration of a cholecystokinin analogue, ceruletide, protects against ischemia-induced neurodegeneration in gerbils. Eur J Pharmacol 1992;214:149-158.
17. Etou K, Kuroki T, Kawahara T, Yonezawa Y, Tashiro N, Uchimura H. Ceruletide inhibits phencyclidine-induced dopamine and serotonin release in rat prefrontal cortex. Pharmacol Biochem Behav 1998;61:427-434.
18. Fujimoto M, Igano K, Watanabe K, Irie I, Inouye K, Okabayashi T. Effects of ceruletide-related peptides on cholecystokinin receptor bindings in brain and pancreas. Biochem Pharmacol 1985;34:1103-1107.
19. A receptors. Eur JPharmacol 1993;238:127-130.
20. Gerlach J, Reisby N, Randrup A. Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychopharmacology 1974;34:21-35.
21. Hagino Y, Moroji T. Effects of systemically administered ceruletide on the in vivo release and metabolism of dopamine in the medial prefrontal cortex of awake, freely moving rats: an in vivo microdialysis study. Brain Res 1994;644:40-46.
22. Hagino Y, Moroji T, Iizuka R. A behavioral pharmacological study on intracerebroventricularly administered CCK-8 related peptides in mice. Neuropeptides 1989;13:107-113.
23. Hamamura T, Kazahaya Y, Otsuki S. Ceruletide suppresses endogenous dopamine release via vagal afferent system, studied by in vivo intracerebral dialysis. Brain Res 1989;483:78-83.
24. A receptor antagonist, L-364,718 (MK-329). Psychopharmacology 1990;101:384-389.
25. Hamilton M, Sheehan MJ, de Belleroche J, Herberg LJ. The cholecystokinin analogue, caerulein, does not modulate dopamine release or dopamine-induced locomotor activity in the nucleus accumbens of rat. Neurosci Lett 1984;44:77-82.
26. Harro J, Pöld M, Vasar E. Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: Influence of acute and subchronic diazepam treatment. Naunyn Schmiedeberg's Arch Pharmacol 1990;341:62-67.
27. B receptors mediate the regulation of exploratory behaviour in the rat. Eur J Pharmacol 1991;193:379-381.
28. B receptor activation reduces glutamate-induced depolarization in slices of rat cerebral cortex. J Neural Transm Gen Sect 1993;93:61-66.
29. Hashimoto T, Yanagisawa N. Acute reduction and long-term improvement of cho.rea with ceruletide (cholecystokinin analogue). J Neurol Sci 1990;100:178-185.
30. Hill DR, Woodruff GN. Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260. Brain Res 1990;276-283.
31. Hirata H, Ogawa N, Asanuma.M, Ota Z, Mori A. Effect of chronic ceruletide treatment on dopaminergic neurotransmitters, receptors and their mRNA in the striatum of rats with dyskinesia induced by iminodipropionitrile. Brain Res 1993;604:197-204.
32. Hirayama K, Kamitsukasa I, Tokumaru Y, Yamada T. The effects of ceruletide for Meige's syndrome - Is it effective for a long period? In: Sofue I, ed. Neuropeptide: Basis and clinics. Nagoya: The Committee on Research and Development of Neuropeptides for the Treatment of Neurological and Psychiatric Disorders, sponsored by the Ministry of Health and Welfare, Japan, 1991;284-289 (in Japanese).
33. Hökfelt T, Rehfeld JF, Skirboll L, Ivemark B, Goldstein M, Markey K. Evidence for coexistence of dopamine and CCK in mesolimbic neurons. Nature 1980;285:476-478.
34. Hökfelt T, Skirboll L, Rehfeld IF, Goldstein M, Markey K, Dann O. A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: Evidence from immunohistochemistry combined with retrograde tracing. Neuroscience 1980;5:2093-2124.
35. Hommer DW, Palkovits M, Crawley JN, Paul SM, Skirboll LR. Cholecystokinin-induced excitation in the substantia nigra: Evidence for peripheral and central components. J Neurosci 1985;5:1387-1392.
36. Hughes J, Boden P, Costall B, et al. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 1990;87:6728-6732.
37. Ito S, Takashima A, Igano K, Inouye K. Memory effect of caerulein and its analogs in active and passive avoidance responses in the rat. Peptides 1989;10:843-848.
38. Ito S, Takashima A, Maeda Y. Protective effect of cerulein on memory impairment induced by protein synthesis inhibitors in rats. Peptides 1992;13:1007-1012.
39. Iwasaki Y, Kinoshita M, Ikeda K, Shiojima T. Palatal myoclonus following Behçet's disease ameliorated by ceruletide, a potent analogue of CCK octapeptide. J Neural Sci 1991;105:12-13.
40. Katsuura G, Shinohara S, Shintaku H, Eigyo M, Matsushita A. Protective effect of CCK-8 and ceruletide on glutamate-induced neuronal cell death: Possible involvement of CCK-B receptors. Neurosci Lett 1991;132:159-162.
41. Kihara T, Ikeda M, Ibii N, Matsushita A. Ceruletide, a cholecystokinin-related peptide, attenuates haloperidol-induced increase in dopamine release from the rat striatum: An in vivo microdialysis study. Brain Res 1990;519:44-49.
42. Kihara T, Ikeda M, Ibii N, Matsushita A. Ceruletide, a CCK-like peptide, attenuates dopamine release from the rat striatum via a central site of action. Brain Res 1992;588:270-276.
43. Kihara T, Ikeda M, Ibii N, Matsubara K, Matsushita A. Differential effects of ceruletide on amphetamine-induced behaviors and regional dopamine release in the rat. Eur J Pharmacol 1993;230:271-277.
44. Kihara T, Ikeda M, Miyazaki H, Matsushita M. Influence of potassium concentration in microdialysis. perfusate on basal and stimulated striatal dopamine release: Effect of ceruletide, a cholecystokinin-related peptide. J Neurochem 1993;61:1859-1864.
45. Kojima T, Yamauchi T, Miyasaka M, et al. Treatment of tardive dyskinesia with ceruletide: A double-blind, placebo-controlled study. Psychiatry Res 1992;43:129-136.
46. Koshikawa N, Kikuchi de Beltran K, Saigusa T, Kobayashi M, Stephenson JD. Cholecystokinin octapeptide and caerulein injection into the dorsomedial nucleus accumbens potentiate apomorphine-induced jaw movements in rats. Eur J Pharmacol 1991;209:75-80.
47. Kuribara H. Ceruletide, a cholecystokinin-like decapeptide, differentially reduces the stimulant effect of MK-801 and ketamine: Evaluation by discrete shuttle avoidance in mice. Eur J Pharmacol 1993;231:7-11.
48. Kuribara H. Contrasting effects on methamphetamine sensitization of ceruletide, a cholecystokinin-like decapeptide, and haloperidol. Psychopharmacology 1995;120:75-80.
49. Kuroki T, Tatebayashi Y, Ide K, et al. Antagonism of ceruletide, a cholecystokinin analog, to the neurochemical effects of the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonists, phencyclidine and MK-801, on regional dopaminergic neurons in the rat brain. Neuropeptides 1992;21:167-173.
50. Lydiard RB, Ballenger JC, Laraia MT, Fossey MD, Beinfeld MC. CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects. Am J Psychiatry 1992;49:691-693.
51. Magnani M, Mantovani P, Pepeu G. Effect of cholecystokinin octapeptide and ceruletide on release oface-tylcholine from cerebral cortex of the rat in vivo. Neuropharmacology 1984;23:1305-1309.
52. B receptors in behavioural and hormonal studies in rats. Naunyn Schmiedeberg's Arch Pharmacol 1994;349:478-484.
53. Mano Y, Nakamura T, Takayanagi T, Mayer RF. Ceruletide therapy in action tremor following thalamic hemorrhage. J Neurol 1993;240:144-148.
54. 1-receptor agonist SKF 38393. Jpn JPharmacol 1992;60:141-144.
55. Matsubara K, Malsushima A. Long-lasting reduction of amphetamine-induced hyperactivity in rats after combined administration of caerulein with haloperidol. Eur J Pharmacol 1984;191:157-58.
56. Matsumoto T, Nakahara T, Uchimura H, et al. Effects of systemically administered caerulein on dopamine metabolism in rat brain. Brain Res 1984;324:195-199.
57. Matsunaga T, Ohyama S, Takehara S, et al. The effect of ceruletide on tardive dyskinesia: A double blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:533-539.
58. Maurice T, Hiramatsu M, Kameyama T, Hasegawa T, Nabeshima T. Cholecystokinin-related peptides, after systemic or central administration, prevent carbon monoxide-induced amnesia in mice. J Pharmacol Exp Ther 1994;269:665-673.
59. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruption associated with the prefrontal cortex. J Neurosci 1997;17:2921-2927.
60. Montgomery SA, Green MC. The use of cholecystokinin in schizophrenia: A review. Psychol Med 1988;18:593-603.
61. Moran T, Robinson PH, Goldrich MS, McHugh PR. Two brain cholecystokinin receptors: Implications for behavioral actions. Brain Res 1986;362:175-179.
62. Moroji T, Hagino Y. A behavioral pharmacological study on CCK-8 related peptides in mice. Neuropeptides 1986;8:273-286.
63. Moroji T, Hagino Y. Bilateral subdiaphragmatic vagotomy does not prevent the behavioral effects of system-atically administered ceruletide in mice. Neuropeptides 1987;9:217-224.
64. Moroji T, Okuyama T, Tsunashima K, Matsuzaki I. A neuroendocrinological study of responders and non-responders to ceruletide treatment in chronic neuroleptic-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1987;11:49-64.
65. Moroji T, Watanabe N, Aoki N, Itoh K. Antipsychotic effects of ceruletide (caerulein) on chronic schizophrenia. Arch Gen Psychiatry 1982;39:485-486.
66. Mueller K, Peel JL, Rewey KL. Effects of caerulein + haloperidol on amphetamine-induced locomotor stereotypy in rats. Life Sci 1989;44:717-724.
67. Murphy BL, Amsten AF, Goldman-Rakic PS, Roth RH. Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proc Natl Acad Sci USA 1996;93:1325-1329.
68. Nagahama H. Acute and long-lasting effects of peripheral injection of caerulein and CCK-8 on the central GABAergic system in mice. Peptides 1989;10:1247-1251.
69. Nair NPV, Lal S, Bloom DM. Cholecystokinin and schizophrenia. Prog Brain Res 1986;65:237-258.
70. Nakamura K, Matsumoto T, Hirano M, Uchimura H. Changes in GABA content and turnover in discrete regions of rat brain after systemic administration of caerulein. Psychopharmacology 1990;101:73-76.
71. Nishikawa T, Tanaka M, Koga I, Uchida Y. Biphasic and long-lasting effect of ceruletide on tardive dyskinesia. Psychopharmacology 1985;86:43-44.
72. Nishikawa T, Tanaka M, Tsuda A, Kuwahara H, Koga I, Uchida Y. Effect of ceruletide on tardive dyskinesia: A pilot study of quantitative computer analyses on electromyogram and microvibration. Psychopharmacology 1986;90:5-8.
73. Nishikawa T, Tanaka M, Tsuda A, Koga I, Uchida Y. Ceruletide for tardive dyskinesia. Biol Psychiatry 1987:22:796-801.
74. Ogawa N, Haba K, Asanuma M, Mori A. Long-lasting effect of ceruletide on dyskinesia and monoaminergic neuronal pathways in rats treated with iminodipropionitrile. Brain Res 1991;556:271-279.
75. Ohmoto T, Mizobuchi M, Mino S, Yamaguchi F, Itano T, Hatase O. Effect of ceruletide on involuntary movements in monkey and rat. In: Sofue I, ed. Neuropeptide: Basis and Clinics. Nagoya: The Committee on Research and Development of Neuropeptides for the Treatment of Neurological and Psychiatric Disorders, sponsored by the Ministry of Health and Welfare, Japan, 1990;309-313 (in Japanese).
76. Oldendorf WH. Blood-brain barrier permeability to peptides: Pitfalls in measurement. Peptides (Suppl 2) 1981;2:109-111.
77. Pietrowsky R, Fehm HL, Er A, Bathelt B, Born J. Influences of the cholecystokinin analog ceruletide on human sleep and evoked potentials. Neuropsychobiology 1990;23:41-47.
78. Pietrowsky R, Specht G, Fehm HL, Born J. Comparison of satiating effects of ceruletide and food intake using behavioral and electrophysiological indicators of memory. Int J Psychophysiol 1994;17:79-89.
79. Ravard S, Dourish CT. Cholecystokinin and anxiety. Trends Pharmacol Sci 1990;11:271-273.
80. Sargent EN, Boswell W, Hubsher J. Cholecystokinetic cholecystography: Efficacy and tolerance studies of ceruletide. Am J Roentgenol 1978;130:1051-1055.
81. Reeve JR, Jr., Eysselein V, Solomon TE, Go VLW. Cholecystokinin. Ann NY Acad Sci 1994;713:1-467.
82. Schreiber H, Stolz-Born G, Pietrowsky R, Kornhuber HH, Fehm HL, Bom J. Improved event-related potential signs of selective attention after the administration of the cholecystokinin analog ceruletide in healthy persons. Biol Psychiatry 1995;37:702-712.
83. Shimoyama M, Kito S. Effect of cerulein on in vivo release of acetylcholine from the rat striatum. Brain Res 1989;492:381-384.
84. Shinohara S, Katsuura G, Eigyo M, Shintaku H, Ibii N, Matsushita A. Inhibitory effect of CCK-8 and ceruletide on glutamate-induced rises in intracellular free calcium concentrations in rat neuron cultures. Brain Res 1992;588:223-228.
85. Skirboll LR, Grace AA, Hommer DW, et al. Peptide-monoamine coexistence: Studies of the actions of cholecystokinin-like peptide on the electrical activity of midbrain dopamine neuron. Neuroscience 1981;6:2111-2124.
86. Sofue I, ed. Neuropeptide: Basis and Clinics. Nagoya: The Committee on Research and Development of Neuropeptides for the Treatment of Neurological and Psychiatric Disorders, sponsored by the Ministry of Health and Welfare, Japan, 1991;207-309 (in Japanese).
87. Takahashi K, Urakami K, Awaki E, Hamasaki N, Adachi Y, Takao T. Clinical and biochemical effects of ceruletide on dementia of the Alzheimer type. In: Sofue I, ed. Neuropeptide: Basis and Clinics. Nagoya: The Committee on Research and Development of Neuropeptides for the Treatment of Neurological and Psychiatric Disorders, sponsored by the Ministry of Health and Welfare, Japan, 1989;335-338 (in Japanese).
88. Takashima A, Maeda Y, Itoh S. Influence of chronic intracerebroventricular infusion of vasoactive intestinal peptide (VIP) on memory processes in Morris water maze pool test in the rat. Peptides 1993;14:1073-1078.
89. Takashima A, Yokota T, Maeda Y, Itoh S. Pretreatment with caerulein protects against memory impairment induced by protein kinase C inhibitors in rat. Peptides 1991;12:699-703.
90. Takeda Y, Hoshino M, Yanaihara N, et al. Comparison of CCK-8 receptors in the pancreas and brain of rats using CCK-8 analogues. Jpn J Pharmacol 1989;49:471-481.
91. Tamura Y, Sato Y, Akaike A, Shiomi H. Mechanisms of cholecystokinin-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res 1992;592:317-325.
92. Tokiwa T, Uemura I, Murakami H, et al. Studies on caerulein (FI6934). Absorption, distribution, metabolism and excretion of caerulein. Jpn J Pharmacol 1975;25:747-762.
93. Uchihashi Y, Kuribara H, Tadokoro S. Assessment of the ambulation-increasing effect of ketamine by co-administration with central-acting drugs in mice. Jpn J Pharmacol 1992;60:25-31.
94. Vanderhaeghen JJ, Crawley JN, eds. Neuronal cholecystokinin. Ann NY Acad Sci 1985;448:1-697.
95. Vanderhaeghen JJ, Signeau JC, Gepts W. New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature 1975;257:604-605.
96. 3H]cholecystokinin-8 as radioligand. J Neurosci 1984;4:1021-1033.
97. Vasar E, Harro J, Lang A, Pöld A, Soosaar A. Differential involvement of CCK-A and CCK-B receptors in the regulation of locomotor activity in the mouse. Psychopharmacology 1991;105:393-399.
98. Vasar E, Lang A, Harro J, et al. Subdiaphragmatic vagotomy does not prevent the anti-exploratory effect of caerulein in the elevated plus-maze. Neuropeptides 1994;26:39-45.
99. 3H]propionylated-CCK-8 binding after repeated administration of drugs affecting cholecystokinin receptors. Eur J Pharmacol 1991;202:385-390.
100. Vincent ME, Wetzner SM, Robbins AH. Pharmacology, clinical uses, and adverse effects of ceruletide, a cholecystokinetic agent. Pharmacotherapy 1982;2:223-234.
101. Woodruff GN, Hughes J. Cholecystokinin antagonists. Ann Rev Pharmacol Toxicol 1991;1:469-501.
102. Zetler G. Central effects of ceruletide analogues. Peptides (Suppl 2) 1981;2:65-69.
103. Zetler G. Caerulein and its analogues: Neuropharmacological properties. Peptides (Suppl 3) 1985;6:33-46.
104. Zetler G. Neuropharmacological profile of cholecystokinin-like peptides. Ann NY Acad Sci 1985;48:448-469.
105. Zhu XG, Greeley GH, Jr., Lewis BG, Lilja P, Thompson JC. Blood-CSF barrier to CCK and effect of centrally administered bombesin on release of brain CCK. J Neurosci Res 1986;15:393-403.